Bausch & Lomb

BioPharma, Devices & Diagnostics

Bausch + Lomb’s IPO plans come into focus as BHC prepares to split into three

Bausch + Lomb is returning to the public markets in an IPO expected to rank among the biggest in healthcare. Speaking at the annual J.P. Morgan Healthcare Conference, Bausch Health Companies CEO Joe Papa discussed the plans to spin off both the iconic eye products business as well as the skin products business, leaving three independent and publicly traded companies.